AcelRx pulls in $250M for opioid drug-device combo Zalviso; Unilife signs deal for its Ocu-Jet eye drug delivery system;

> AcelRx ($ACRX) teamed up with Germany's Grunenthal to develop its late-stage opioid drug-device combination Zalviso in Europe. AcelRx will pick up $30 million up front and up to $220 million in milestone payments moving forward. Story

> Unilife ($UNIS) signed an agreement with a "global pharmaceutical company" for the use of Unilife's Ocu-Jet delivery system for injectable treatments in the eye. Unilife has forged several high-profile partnerships in recent months. Release

> Researchers at Western University are working on a delivery nanostructure to carry pain meds directly to bones. More

> OncoSec Medical heralded positive Phase II data for its immunotherapy to treat solid tumors. The treatment uses the company's electroporation technology to deliver the cancer drug directly into the tumor. Release

> Moberg Pharma reported positive interim Phase II results of its topical formulation for the treatment of nail fungus. Release

> Insite Vision announced positive Phase III results for its eye drops to reduce inflammation and pain after cataract surgery. Release

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.